BRI is an RTP-based biotechnology company focused on harnessing the natural power of enzymes. Through the discovery and development of innovative animal feed enzymes, BRI hopes to create a future for animal agriculture that is both economically and environmentally sustainable from farm to fork.
Founded by father and son team Drs. Jason and Giles Shih, BRI has developed two products, Versazyme®and Valkerase®, which are distributed to more than 80 countries worldwide. BRI continues to research science-based solutions to aid growing agricultural and industrial markets around the world. BRI signed a formal agreement to construct a manufacturing facility in China. BRI has partnered with Taiwan-based Yung Zip Chemical and Yung Shin Pharmaceutical to purchase the land and begin construction. Estimated at $8 million, the project is privately funded in a 40/40/20 split, BRI and YZC are covering the lion’s share.
